<DOC>
	<DOCNO>NCT00866996</DOCNO>
	<brief_summary>The purpose study well understand treatment outcomes extended-release methylphenidate atomoxetine child attention-deficit hyperactivity disorder ( ADHD ) evaluate physicians parent community setting .</brief_summary>
	<brief_title>Community-based Study Comparing Extended-release Methylphenidate Atomoxetine Children With Attention-deficit Hyperactivity Disorder</brief_title>
	<detailed_description>Methylphenidate atomoxetine available treatment ADHD child . Methylphenidate think block reuptake norepinephrine dopamine presynaptic neuron increase release monamines extraneuronal space . The mechanism atomoxetine produce therapeutic effect think related selective inhibition presynaptic norephinephrine transporter . This multi-center , randomize , open-labeled , parallel design study extended-release methylphenidate atomoxetine child age 6 12 year ADHD evaluate physician parent . Children randomly assign ( 2:1 , respectively ) 3 week treatment extended-release methylphenidate atomoxetine . Physicians evaluate treatment use ADHD Rating Scale ( ADHD-RS ) Clinical Global Impression-Improvement Illness scale ( CGI-I ) . Assessments make prior beginning treatment ( screen ) , telephone interview 1 week begin treatment , clinic visit 2 week begin treatment , final clinic visit ( 3 week ) . Parents assess treatment use Parent Satisfaction Questionnaire ( PSQ ) treatment day 2 13 clinical visit 3 week begin treatment . The question interest include whether difference treatment improvement behavior timing difference . Vital sign , height , weight also record adverse event . Study drug take orally day . Patients randomly assign extended-release methylphenidate begin treatment 18 mg/day . Patients randomly assign atomoxetine begin treatment 0.5 mg/kg/day . The study medication titrate consider appropriate patient 's physician . The duration treatment 21 day .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Patients meet DSMIV criterion primary diagnosis ADHD subtype ( may newly diagnose ADHD treatment ) score 24 high ADHD Rating Scale ( ADHDRS ) screen physician must rat patient `` Moderately ill '' bad CGIS screen child may enrol receive adequate treatment ADHD ( base clinical judgment consultation parent ) child must washedout current treatment minimum 3 day 5 half life medication whichever long child parent must give write informed consent , assent , applicable . Female child experience menarche presence eat substance disorder comorbid psychiatric condition oppositional defiant disorder history seizure , tic disorder , mental retardation , severe developmental disorder ( i.e . severe cerebral palsy , autism ) family history Tourette 's Disorder require medication excluded package insert Concerta Strattera diagnose hyperthyroidism glaucoma know nonresponders treatment indicate ADHD .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Attention deficit hyperactivity disorder</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Atomoxetine</keyword>
	<keyword>Concerta</keyword>
</DOC>